KURN.SW Kuros Biosciences up 10.84% to CHF29.24: earnings today 10 Mar 2026, watch guidance

KURN.SW stock jumps 10.84% intraday to CHF29.24 as Kuros Biosciences AG (SIX) heads into its earnings announcement on 10 Mar 2026. The move comes on volume of 560,432.00 shares and follows a gap open at CHF27.70. Investors will watch revenue trends, the company’s EPS of -0.12, and management comments on orthobiologics sales. This earnings spotlight frames today’s price action against Kuros’s pipeline progress and sector comparatives in Swiss healthcare.

Earnings context for KURN.SW stock

Kuros reports after market today; the official earnings time is 10 Mar 2026 16:30 UTC. One clear fact: the market priced a short-term re-rating into the stock before results. Yesterday’s close was CHF26.38, intraday range is CHF27.70–30.30, and the stock now trades at CHF29.24. Analyst focus will be on revenue cadence from MagnetOs products and updates to late-stage programs such as KUR-111 and KUR-113.

Expect questions on commercialization and gross margin trends. Kuros operates in the Biotechnology industry within the Swiss Healthcare sector, where peers trade at an average PE of 30.01. Kuros’s current metrics (EPS -0.12, PE -221.50) reflect a loss-making R&D phase company with commercial lines.

Financial snapshot and valuation metrics for KURN.SW stock

Key figures matter ahead of the call: Market Cap CHF1,041,279,474.00, Revenue per Share TTM CHF2.69, Book Value per Share CHF1.93, and Cash per Share CHF0.45. Kuros shows a current ratio 2.25 and low debt burden (debt/equity 0.02), which supports runway for clinical work.

Valuation is stretched versus sector averages. Price-to-sales is 9.71, price-to-book is 13.80, and EV/Revenue is 9.56. Those multiples imply high growth expectations; any revenue miss could pressure the stock given the premium valuation.

Meyka grade and KURN.SW stock forecast

Meyka AI rates KURN.SW with a score out of 100: 71.87 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and we are not financial advisors.

Meyka AI’s forecast model projects yearly target CHF34.56, implying an upside of 18.19% versus the current CHF29.24. Shorter-term model outputs are Monthly CHF24.17 (downside -17.32%) and Quarterly CHF25.03 (downside -14.41%). Forecasts are model-based projections and not guarantees.

Technical and trading signals for KURN.SW stock

Technicals paint a neutral-to-bullish near-term picture. Key indicators: RSI 50.89, MACD 0.13 (signal 0.02), and ADX 20.27. The 50-day average is CHF26.55 and the 200-day average is CHF27.27, both below today’s price, which supports the intraday bounce.

Volume is notable: 560,432.00 vs average 138,961.00, a 4x spike that confirms conviction. Watch support at CHF27.70 and resistance at the year high CHF34.20 for next stops.

Risks, catalysts and sector context for KURN.SW stock

Primary risks: clinical trial setbacks, slower commercialization of orthobiologics, and revenue misses given high multiples. Kuros’s profitability metrics (net margin negative and earnings yield negative) show dependence on successful product rollout.

Catalysts include positive trial readouts for KUR-111/KUR-113, stronger MagnetOs sales in EU/US, and clear 2026 guidance. In Swiss Healthcare, average sector PE is 30.01 and average PB is 4.85, meaning Kuros trades at a premium and will need tangible growth to justify valuation.

Model price targets and scenarios for KURN.SW stock

We outline three scenario price points aligned with Meyka forecasts and company risk: Conservative (near-term) CHF25.03 based on quarterly model output; Base (12 months) CHF34.56 from the Meyka yearly model; Bull (3 years) CHF47.45 aligned with a successful commercialization and pipeline execution. Implied moves: Conservative -14.41%, Base +18.19%, Bull +62.16% versus today’s CHF29.24.

Use these targets as framework, not trading instructions. For company filings and press, see Kuros investor site and the SIX exchange overview of listings.

Final Thoughts

Kuros Biosciences (KURN.SW) trades at CHF29.24 after a 10.84% intraday jump as markets position for the 10 Mar 2026 earnings release. The company combines commercial orthobiologics revenue with ongoing clinical programs; that mix explains a premium valuation (P/S 9.71, P/B 13.80). Meyka AI’s forecast model projects a yearly target CHF34.56, implying an 18.19% upside from current levels, while shorter-term model outputs flag downside risk to CHF25.03. Our grade, B+ (71.87/100), balances sector opportunity and execution risk. Traders should watch management guidance, product sales cadence, and trial updates; positive surprises could justify the premium, while revenue or R&D setbacks could force a repricing. Meyka AI provides this analysis as an AI-powered market analysis platform; forecasts are model outputs and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.